Hemorrhagic profile of the fibrinolytic alfimeprase after ischemia and reperfusion

Neurological Research

Volumn 31, Issue 2, 2009, Pages 209-214

  Lu, Aigang ^a   Kurosawa, Yuko ^a   Luskey, Kenneth ^a   Pyne Geithman, Gail ^a   Caudell, Danielle ^a   Clark, Joseph ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Alfimeprase; Blood brain barrier permeability; Cerebral ischemia; Hemorrhagic transformation; Infarction

Indexed keywords

ALFIMEPRASE; ALTEPLASE;

ANESTHESIA; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN HEMORRHAGE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; BRAIN TISSUE; CONTROLLED STUDY; DECAPITATION; FROZEN SECTION; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MORTALITY; NEUROLOGIC DISEASE; NONHUMAN; RAT; REPERFUSION INJURY; SUTURE REMOVAL;

ANIMALS; BLOOD-BRAIN BARRIER; BODY WEIGHT; BRAIN EDEMA; CAPILLARY PERMEABILITY; CEREBRAL HEMORRHAGE; CHI-SQUARE DISTRIBUTION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FIBRINOLYTIC AGENTS; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; METALLOENDOPEPTIDASES; NEUROLOGIC EXAMINATION; RATS; REPERFUSION INJURY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 62849085809     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/174313209X393933     Document Type: Article

References (13)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333: 1581-1587
2. Retzios AD, Markland FS, Jr. A direct-acting fibrinolytic enzyme from the venom of Agkistrodon contortrix contortrix: Effects on various components of the human blood coagulation and fibrinolysis systems. Thromb Res 1988;52: 541-552
3. Retzios AD, Markland FS, Jr. Fibrinolytic enzymes from the venoms of Agkistrodon contortrix contortrix and Crotalus basilis- cus basiliscus: Cleavage site specificity towards the alpha-chain of fibrin. Thromb Res 1994;74: 355-367
4. Karibe H, Zarow GJ, Graham SH. Mild intraischemic hypothermia reduces postischemic hyperperfusion, delayed postischemic hypo- perfusion, blood-brain barrier disruption, brain edema, and neuronal damage volume after temporary focal cerebral ischemia in rats. J Cereb Blood Flow Metab 1994;14: 620-627
5. Nito C, Kamiya T, Ueda M. Mild hypothermia enhances the neuroprotective effects of FK506 and expands its therapeutic window following transient focal ischemia in rats. Brain Res 2004; 1008: 179-185
6. Zhang RL, Chopp M, Zhang ZG, et al. A rat model of focal embolic cerebral ischemia. Brain Res 1997;766: 83-92
7. Maier C, Ahern K, Cheng M, et al. Optimal depth and duration of mild hypothermia in a focal model of transient cerebral ischemia. Effects on neurologic outcome, infarct size, apoptosis, and inflammation. Stroke 1998;29: 2171-2180
8. Kenyon P, Bertoli L, De MaioJ, etal. Phase II trial of alfimeprase, a novel-acting fibrin degradation agent, for occluded central venous access devices. JClin Oncol 2006; 24: 3056-3060
9. Ropper A. Ischaemic brain oedema. JClin Neurosci 2002; 9: 113-124
10. Deitcher S, Begelman S, on behalf of the novel arterial perfusion with alfimeprase (NAPA-1) investigators. Alfimeprase, a novel direct-acting fibrinolytic agent in acute peripheral arterial occlu-sion. Report of a phase 2, multi-center, open-label, dose-defining study (NAPA-1). Circulation 2006; 114: 648
11. Ouriel K, Cynamon J, Weaver F, et al. A phase I trial of alfimeprase for peripheral arterial thrombolysis. J Vasc Interv Radiol 2005;16: 1075-1083
12. Deitcher S, Funk W, Buchanan J, et al. Alfimeprase. A novel recombinant direct-acting fibrinolytic. Expert Opin Biol Ther2006; 6: 1361-1369
13. Toombs C. New directions in thrombolytic therapy. Curr Opin Pharmacol 2001;1:164-168